NASDAQ: RDHL - RedHill Biopharma Ltd.

Rentabilidad a seis meses: -23.65%
Sector: Healthcare

Calendario de promoción RedHill Biopharma Ltd.


Acerca de la empresa

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

más detalles
Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

IPO date 2013-01-07
ISIN US7574681034
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.redhillbio.com
Цена ао 0.4797
Cambio de precio por día: +5.5% (6.55)
Cambio de precio por semana.: +6.31% (6.5)
Cambio de precio por mes: -13.19% (7.96)
Cambio de precio en 3 meses.: -19.93% (8.63)
Cambio de precio en seis meses: -23.65% (9.05)
Cambio de precio por año: +370.07% (1.47)
Cambio de precio en 3 años.: +161.74% (2.64)
Cambio de precio en 5 años.: +11.27% (6.21)
Cambio de precio en 10 años.: 0% (6.91)
Cambio de precio desde principios de año.: -4.16% (7.21)

Subestimación

Nombre Significado Calificación
P/S 36.55 1
P/BV 115.06 1
P/E 9.95 9
EV/EBITDA -7.93 0
Total: 5.38

Eficiencia

Nombre Significado Calificación
ROA, % 103.77 10
ROE, % 1155.91 10
Total: 5

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.0399 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 3.38 1
Rentabilidad Ebitda, % -164.64 0
Rentabilidad EPS, % -106.74 0
Total: 0.2



Supervisor Título profesional Pago año de nacimiento
Mr. Dror Ben-Asher Co-Founder, Chairman & CEO 594.61k 1966 (59 años)
Mr. Gilead Raday MPhil, MSc Chief Operating Officer 365.56k 1975 (50 años)
Mr. Adi Frish Chief Corporate & Business Development Officer 339.3k 1970 (55 años)
Mr. Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director 469.8k 1960 (65 años)
Mr. Razi Ingber Chief Financial Officer 339.82k 1984 (41 año)
Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager N/A
Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development 299.29k 1955 (70 años)
Ms. Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs N/A
Mr. Guy Goldberg J.D. Chief Business Officer 338.13k 1976 (49 años)

DIRECCIÓN: Israel, Tel Aviv, 21 Ha’arba’a Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.redhillbio.com